BioMedNewsBreaks – Artella Solutions Inc. Names New Leadership Team Members, Announces Six-State Expansion

Artella Solutions, a company committed to advancing the well-being of patients with rhythm disorders while providing high-quality, real-time data to physicians for immediate viewing, announced that several industry veterans have joined the company’s national sales team as the Texas-based organization expands into six new markets: Arizona, Florida, Ohio, Michigan, New York and Pennsylvania. The strategic expansion is based on Artella’s best opportunities to capture market share and plans are already underway for scaling clinical operations and expert customer service teams to support Artella’s rapid growth. According to the company, its array of solutions and services for both patients and healthcare providers offers customized solutions for an easier alternate to in-hospital ECG and cardiac monitoring. The company’s proprietary online, device-agnostic health platform enables data to be collected, live streamed and integrated and then seamlessly utilized during patients’ daily activities to improve quality of life for patients and reduce costs for institutions and providers. In addition to the sales team growth, the company also announced the appointment of several new key leadership team members, including Jacinta Fitzsimons as EVP of clinical operations; Joseph K. Hashim, EVP of commercialization and corporate strategy; Linda Nelson, VP of revenue cycle operations; and Ramesh Hariharan as medical director. “Artella is a very special, one-of-a-kind company that bridges opportunity, technology and people who have verifiable industry backgrounds of success in our space,” said Artella Solutions board chair Larry Lawson in the press release. “Our technology, coupled with our unsurpassed level of service, is what we are. Artella has begun its growth and is destined to write a new chapter in cardiac patient monitoring.”

To view the full press release, visit https://ibn.fm/MrrbZ

About Artella Solutions Inc.

Artella Solution is a digital healthcare company monitoring patients’ heart rhythms and assisting physicians’ paths from care to cure utilizing the latest patch technology to detect and capture abnormal changes in heart rhythms. The company offers healthcare providers one system that meets the diagnostic needs of physicians to easily monitor, diagnose and treat patients while ensuring clinical and economic benefits for providers and patients alike. For more information, visit the company’s website at www.ArtellaInc.com

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

2 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

3 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

3 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

5 days ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of…

6 days ago

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…

6 days ago